baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Ionis Pharmaceuticals/ US4622221004 /

9/13/2024 9:59:59 PM	Chg. +1.13	Volume	Bid-	Ask-	High	Low
42.18USD	+2.75%	75,334 Turnover: 3.17 mill.	-Bid Size: -	-Ask Size: -	42.84	41.28

GlobeNewswire 8/13 Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2024 Financial Resul...

Newsfile Corp 7/17 Analysts Hunt for Undervalued Biotech Stocks

GlobeNewswire 5/30 Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a R...

GlobeNewswire 5/16 Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lat...

GlobeNewswire 5/13 Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Result...

GlobeNewswire 5/7 Vect-Horus to Take Part in a Roundtable Discussion at Viva Technology Conference

GlobeNewswire 4/23 ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held M...

GlobeNewswire 4/22 Vect-Horus Publication in Pharmaceutics Outlines How Vectors Can Improve Delivery of Therapeutics to...

GlobeNewswire 3/6 New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) i...

GlobeNewswire 3/5 Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 F...

GlobeNewswire 2/23 Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positiv...

GlobeNewswire 1/8 Praxis Precision Medicines Provides Update on Advancing Clinical Stage Portfolio

TeleTrader 12/22/2023 US FDA approves AstraZeneca-Ionis's medicine

GlobeNewswire 3/28/2022 Biogen and Ionis Announce Topline Phase 1 Study Results of Investigational Drug in C9orf72 Amyotroph...

GlobeNewswire 3/17/2022 Ring Therapeutics Announces the Appointment of Industry Leaders to its Board of Directors

GlobeNewswire 3/14/2022 Biogen Announces New Updates Across its SMA Research Program at 2022 MDA Conference

GlobeNewswire 3/9/2022 Antisense Therapeutics to present poster at world’s largest NMD conference

GlobeNewswire 2/24/2022 ProQR Announces Fourth Quarter and Full Year 2021 Operating and Financial Results

GlobeNewswire 2/2/2022 n-Lorem Foundation Partners with Argonaut to Manufacture ASO Medicines for Patients with Nano-rare D...

GlobeNewswire 1/4/2022 Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA

GlobeNewswire 1/3/2022 Indaptus Therapeutics Announces Appointment of Boyan Litchev, M.D. as Chief Medical Officer

GlobeNewswire 12/10/2021 Cytokinetics Announces Data From Its ALS Program Presented at the 32nd International Symposium on AL...

GlobeNewswire 11/18/2021 ProQR Announces Highlights from Analyst Event

GlobeNewswire 11/15/2021 CoImmune, Inc. Appoints Ed Baracchini, PhD, Chairman of the Board of Directors

GlobeNewswire 11/4/2021 ProQR Announces Third Quarter 2021 Operating and Financial Results

Ionis Pharmaceuticals/ US4622221004 /

If you wish to receive reply to your feedback, please provide your email address.